WuXi AppTec Lab Testing Division and AutoGenomics Form Strategic Partnership to Introduce Advanced Molecular...

We are excited about WuXi’s Laboratory Testing Division (LTD)’s new exclusive distributor agreement with AutoGenomics, a U.S.-based molecular diagnostic BioFilmChip® microarray platform company with a current menu of 65 tests. Under the...

WuXi’s STA Subsidiary Passed Third U.S. FDA Inspection

We are pleased to announce that the small molecule active pharmaceutical ingredient (API) and advanced intermediate manufacturing facility located in Jinshan Shanghai, which is part of our subsidiary Shanghai SynTheAll Pharmaceutical...

WuXi’s STA Subsidiary Opens Operations in San Diego

We are delighted to announce that WuXi’s small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), is opening operations in San Diego. STA will provide process R&D and...

WuXi’s BIO 2016 Recap

Last week over 15,000 industry leaders from around the world gathered in San Francisco for the 2016 International BIO Convention to partner and learn about the latest in research, innovation, and...

The China Precision Medicine Cloud: A World-leading Platform to Benefit Patients and Health

We are pleased to announce that we have launched the China Precision Medicine Cloud with Huawei  and WuXi NextCODE at a ceremony in Shanghai. This platform brings together three unique elements: Huawei’s...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS